64 results on '"Tam, Constantine"'
Search Results
2. Health-related quality of life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab
3. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease
4. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program
5. Development of a distributed international patient data registry for hairy cell leukemia
6. Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib
7. Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy
8. Zanubrutinib for the treatment of Waldenström Macroglobulinemia
9. Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond
10. Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL
11. Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy
12. Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance
13. Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?
14. The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
15. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia
16. Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia
17. Systematic literature review of the global burden of illness of mantle cell lymphoma
18. High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia – lessons for immunopathogenesis and prescribing
19. Managing patients with ibrutinib-resistant CLL: don’t stop ibrutinib until you are ready with the next therapy
20. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia
21. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
22. Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware
23. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials
24. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors
25. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib
26. The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma
27. Microvesicles in chronic lymphocytic leukemia: ready for prime time in the clinic?
28. Novel agents versus chemotherapy as frontline treatment of CLL
29. FDG PET in follicular lymphoma: more than a staging test?
30. Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation
31. Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise
32. Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy
33. A novel way to consolidate incomplete responses in chronic lymphocytic leukemia/small lymphocytic lymphoma
34. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/orTP53mutation?
35. Src family kinases and their role in hematological malignancies
36. How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?
37. The utility and limitations of18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review
38. Effective treatment of Waldenström macroglobulinemia associated pure red cell aplasia with standard antilymphomatous chemotherapy
39. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
40. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation
41. CD38 expression in CLL: a dynamic marker of prognosis
42. Protein kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy?
43. Chronic lymphocytic leukemia presenting as an intracranial epidural mass in a patient with myeloproliferative neoplasm associated with JAK2 V617F mutation
44. Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?
45. CARTs to the rescue: therapeutic potential of chimeric antigen receptor T-cells in patients with B-cell malignancies
46. Allogeneic immunity and anti-CD20 therapy: a potent combination in the treatment of a patient with Richter transformation of chronic lymphocytic leukemia
47. Diagnostic techniques and therapeutic challenges in patients withTP53dysfunctional chronic lymphocytic leukemia
48. A case of systemic anaplastic lymphoma kinase-negative anaplastic large cell lymphoma associated with hypereosinophilia, granulomatous myositis and vasculitis
49. Predicting survival in chronic lymphocytic leukemia
50. Modifying the immune system to treat chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.